Introduction
Maintenance of intestinal homeostasis is closely linked to secretory mechanisms controlling fluid and electrolyte secretion, regulated by coordinated actions of a complex network of transporters and ion channels located in the apical and basolateral membranes of intestinal epithelial cells (IEC) . The movement of Cl -ions across the apical membrane of IEC
generates an electrogenic ion current that drives transepithelial sodium flux. This process is further associated with inhibition of sodium/hydrogen exchanger 3 (NHE3)-mediated sodium reabsorption, thereby establishing an osmotic gradient for concomitant movement of water into the luminal compartment.
The main conductive pathway for Cl -ions across the apical membrane of IEC is the anion-selective cystic fibrosis transmembrane conductance regulator (CFTR) channel. Functional activity of this ion channel, which forms membrane-associated, macromolecular complexes including transporters and signaling molecules, is partly regulated by protein kinase A following CFTR coupling to adenylate cyclase, resulting in elevated local concentrations of the second messenger cyclic adenosine 3',5'-monophosphate (cAMP) (Wang et al., 2000; Huang et al., 2001; Li and Naren, 2005) . Multidrug resistance protein 4 (MRP4) is an ubiquitously expressed member of the ATP-binding cassette transporter superfamily, which mediates energy-dependent, unidirectional efflux of prostaglandins and the cyclic nucleotides cAMP and cyclic guanosine 3',5'-monophosphate (cGMP) (Dean et al., 2001; Wielinga et al., 2003; Sager, 2004; Ritter et al., 2005) . The physical and functional coupling of MRP4 with CFTR has been reported, directly implicating MRP4 in spatially restricted and tightly modulated compartmentalization of cAMPsignaling, and regulation of CFTR-induced ion secretion (Li et al., 2007) . Altered ratios of CFTR to MRP4 due to changes in expression and/or subcellular localization, resulting in enhanced or This article has not been copyedited and formatted. The final version may differ from this version.
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J P E T # 2 2 4 3 2 9 5 attenuated CFTR-mediated Cl -transport, have been implicated in the pathology of irritable bowel syndrome with constipation (IBS-C) and secretory diarrhea (Li et al., 2007) , and decreased expression of MRP4 in IBS-C patients has recently been reported (Harrington et al., 2014) .
Guanylate cyclase C (GC-C), a type I transmembrane receptor with intrinsic guanylate cyclase activity, is expressed predominantly on the luminal surface of intestinal epithelial cells along the gastrointestinal tract, is a key regulator of intestinal homeostasis and bowel function (Schulz et al., 1990; Carrithers et al., 1996; Castro et al., 2013; Silos-Santiago et al., 2013) . GC-C is activated by the natural hormones guanylin and uroguanylin, and heat-stable enterotoxin (ST) peptides, members of the guanylin family of cGMP regulating peptides that bind GC-C and activate the intracellular guanylate cyclase domain of the receptor (Currie et al., 1992; Hamra et al., 1993; Kita et al., 1994; Forte 1999 Forte , 2004 . Stimulation of GC-C by these peptides leads to significantly increased intracellular concentrations of cGMP, the sole second messenger generated by GC-C, which is involved in a broad range of physiological processes including activation of cGMP-dependent protein kinase II (PKG-II) (Schlossmann et al., 2005; Pfeiffer et al., 1996) . PKG-II phosphorylation regulates the activity of CFTR, a well-established pathway involved in the regulation of intestinal fluid homeostasis (Seidler et al., 1997; Vaandrager et al., 1998) . More recently, activation of the GC-C/cGMP pathway has also been associated with the modulation of gastrointestinal sensory signaling as a mechanism potentially underlying the analgesic effects of GC-C agonism in models of visceral pain, through an active transport of cGMP into the submucosa following GC-C activation (Eutamene et al., 2010; Castro et al., 2013; Silos-Santiago et al., 2013) . It is not currently known whether MRP4 modulates GC-C mediated cGMP signaling pathways and its potential clinical implications.
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Linaclotide is an orally administered, minimally absorbed, potent and selective agonist of GC-C that has been approved in the United States and European Union for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) and in the United States for chronic idiopathic constipation (CIC) (Lembo et al., 2011; Chey at al., 2012; Rao et al., 2012) . This 14-amino acid peptide is a member of the guanylin family of cGMP-regulating peptides that includes the natural hormones guanylin and uroguanylin Busby et al., 2010 ).
In the studies described here, we have investigated the pharmacological effects of MRP4 inhibition on linaclotide-induced transepithelial ion currents and apical/basolateral cGMP efflux in vitro in rat colon mucosa and propose a novel mechanism that functionally couples compartmentalized linaclotide-induced electrolyte secretion and apical cGMP efflux to spatially restricted regulation by MRP4, following linaclotide activation of the GC-C/cGMP pathway.
JPET Fast Forward. Published on July 27, 2015 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from µl) was added to the luminal chamber for a 60-minute equilibration period, followed by addition of linaclotide (1 µM). To determine the effect of MRP4 inhibition on cGMP secretion, rat colon mucosa was treated with the selective MRP4 inhibitor MK571 (20 µM) added to the apical and basolateral chambers at the 30-minute time point. Aliquots (0.12 ml) from the apical and basolateral chambers were collected in 15-minute intervals to measure cGMP secretion. The volume of KRB solution in both chambers was kept constant throughout the experiment by adding fresh buffer (0.12 ml) to each chamber at the same time aliquots were collected for cGMP measurements. Extracellular cGMP concentrations were determined using the cGMP Biotrak Enzyme Immunoassay System, using the cGMP acetylation protocol (GE Healthcare, Little
Chalfont, UK).
1 0
Measurement of In Vivo cGMP Secretion into the Submucosal Layer by
Microdialysis. Female Sprague-Dawley rats (Harlan Laboratories, Dublin, VA; n=10) were anesthetized (2.54% isoflurane), and middle line laparotomy was performed to expose the proximal colon. Feces were removed by injection of saline (4.5 ml) into the lumen. An isolated segment of proximal colon (colonic loop) was created by two firm ligations 2 cm apart from each other. A linear microdialysis probe consisting of a 5 mm polyacrylonitrile membrane connected on both sides to a polyimide tubing (15 cm) probe was implanted in the colon submucosa layer.
Saline was perfused through the microdialysis probe at a rate of 1 µl/minute and fractions of dialysate were collected during 5 minute intervals. The microdialysis probe was equilibrated for 25 minutes and fractions were collected to determine the basal concentrations of cGMP concentrations in the submucosa (Woo and Lunte, 2008) . protein in the predicted molecular weight range (~125 kDa for the reduced chimera). This chimera had an estimated purity of 85% following protein-A sepharose affinity chromatography and bound antibodies specific to the extracellular portion of human GC-C and IgG 1 (Supplemental Fig. 1A,B) . Furthermore, the GC-C/Fc fusion protein concentration-dependently inhibited linaclotide-induced cGMP secretion from human colon carcinoma T84 cells (Supplemental Fig. 2 ). Addition of this GC-C/Fc fusion protein to the apical chamber resulted in a fast decrease of the linaclotide-stimulated Isc and return to baseline within 15 minutes (Fig. 1) .
The effective concentration of linaclotide which produced 50% of the maximal activity (EC 50 )
increasing transepithelial ion currents in the rat colonic mucosa was 9.2 nM, using a linaclotide concentration-response curve ranging from 1 nM to 1000 nM ( Fig. 2 A,B) .
MRP4 Inhibition Amplifies Linaclotide-induced Transepithelial Ion Currents.
MRP4 mRNA expression has previously been detected in rat mucosal tissue extruded from each This article has not been copyedited and formatted. The final version may differ from this version.
1 2 region of the intestine, ranging from the duodenum to the rectum (Silos-Santiago et al., 2013) .
We further investigated the cellular localization of MRP4 expressed in rat colonic mucosa by immunohistochemistry and found MRP4-specific staining predominantly associated with the apical membrane, indicating high expression of this cGMP transporter on the apical membrane of rat colonocytes, with very minor staining associated with the basolateral membrane also detectable, a pattern similar to that described recently in human and mouse colonic mucosa (Harrington et al., 2014) , and previously reported for human colonic T84 and HT29-CL19A epithelial cells (Li et al., 2007) (Fig. 3) . We further assessed the effects of MK571-mediated inhibition of MRP4 on linaclotide-induced transepithelial ion currents .
Linaclotide effects were measured at concentrations below the calculated EC 50 (6 nM) and at 1000 nM, a concentration of linaclotide that elicits a maximum increase in transepithelial ion currents. Colonic mucosa samples were pretreated with MK571 (20 µM) added to the apical and basolateral chambers, prior to sequential addition of 6 nM and 1000 nM linaclotide for 20-minute incubation periods. During the 20-minute pretreatment period, MK571 elicited no effect on the Isc in rat colon mucosa, compared to vehicle-treated tissue (Fig. 4A ). In the presence either of 6 nM or 1000 nM linaclotide, MK571 augmented linaclotide-induced transepithelial ion currents (Fig. 4A) , and significantly (P<0.05) increased the maximal Isc response at both peptide concentrations (Fig. 4B ). nM) for a 20-minute period to the apical chamber induced a marked increase in transepithelial ion current (Fig. 5A) , which was further potentiated in MK571-pretreated mucosa (Fig. 5B ), but elicited no changes in transepithelial ion currents in sildenafil-pretreated mucosa (Fig. 5C ).
MRP4 Inhibition Differentially Affects
Apical GC-C/Fc fusion protein (60 nM) rapidly abrogated the linaclotide-induced increase in transepithelial ion currents, returning to baseline within 20 minutes. Similar deactivation kinetics of linaclotide-induced transepithelial ion currents were observed in colonic mucosa pretreated either with MK571 or sildenafil, indicating that continuous GC-C stimulation with linaclotide is required to generate increased Isc (Fig. 5A ,B,C)
MRP4 Inhibition Increases Linaclotide-stimulated cGMP Accumulation in Rat
Colon Tissue. In vitro linaclotide-stimulated cGMP accumulation in human colon carcinoma T84 cells has previously been reported . Here, we further investigated the effect of MK571-mediated inhibition of the efflux pump MRP4 on cGMP accumulation in rat colon mucosa. Following in vitro incubation of rat colon mucosa with MK571 (20 µM) added to both the apical and basolateral chambers, no changes in tissue cGMP levels were observed compared to vehicle-treated colon mucosa, while treatment with the phosphodiesterase inhibitor IBMX (100 µM) elicited a significant increase (P<0.01) in cGMP levels (Fig. 6 ). Linaclotide (6, 1000 nM) added to the apical chamber elicited a marked increase in cGMP levels in the colon mucosa, pharmacological effects consistent with activation of GC-C expressed on the apical surface of IEC. Preincubation of linaclotide-treated colon mucosa with MK571 (20 µM) further increased tissue cGMP levels (P<0.01, 1000 nM linaclotide), indicative of a role of MRP4 in this process (Fig. 6 ).
MRP4 Inhibition Decreases Linaclotide-stimulated Apical cGMP Efflux, but has no
Effect on Basolateral cGMP Efflux. Previous studies using surgically ligated intestinal loops This article has not been copyedited and formatted. The final version may differ from this version.
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have demonstrated in vivo linaclotide-stimulated secretion of cGMP into the luminal compartment Busby et al., 2010) . Similarly, linaclotide stimulated in vitro cyclic nucleotide efflux pump-dependent basolateral release of cGMP from polarized Caco-2 cells that was concentration-dependently inhibited by the cGMP transporter inhibitor, probenecid (Castro et al., 2013) . Here, we further investigated the effect of MK571-mediated MRP4 inhibition in vitro on linaclotide-stimulated cGMP secretion from the apical and basolateral sides of rat colonic epithelium. No effects on either apical or basolateral cGMP release were observed during a 60-minute preincubation period with vehicle or MK571 (20 μ M) (Fig. 7A,B) . After 60 minutes, linaclotide (1 μ M) was added to the apical chamber, and aliquots were collected every 15 minutes for another 60 minutes to measure cGMP release from the apical and basolateral sides of the colonic mucosa. Linaclotide stimulated apical cGMP efflux was markedly decreased by MK571 (Fig. 7A ), while basolateral efflux was not affected by MK571 (Fig. 7B) . Kinetics of cGMP efflux indicated an early phase spike in cGMP release from the apical side, with slower but continuous release in the later phase, while cGMP efflux from the basolateral side was characterized by a slow, continuous pattern. Simultaneous recording of transepithelial ion currents throughout the experiment confirmed that linaclotide-induced Isc decreased following MK571 pretreatment of the colonic mucosa (data not shown).
Linaclotide Induces In Vivo cGMP Efflux into the Colonic Submucosal Layers.
Linaclotide-induced cGMP transporter-dependent extracellular release of cGMP from basolateral membranes of IEC is believed to mediate inhibition of colonic nociceptors located in the submucosa, resulting in decreased visceral pain (Castro et al., 2013 , Silos-Santiago et al., 2013 .
However, in vivo release of cGMP from colonic epithelial cells into the colonic submucosal layer has not been studied. We have developed an in vivo colonic microdialysis assay consisting µg) induced a dose-dependent (83%, 90%, 182%, respectively), significant (P<0.001) increase in submucosal cGMP levels after 30 minutes (Fig. 8A) ; the corresponding time course of linaclotide-stimulated cGMP efflux, measured in 5-minute intervals is presented in figure 8B .
Linaclotide-induced increases in submucosal cGMP levels were time-dependent, with the highest dose reaching maximal effect within 12 minutes of linaclotide administration (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. activation by membrane-associated PKGII following activation of the GC-C/cGMP pathway is well documented. Thirdly, the isolation of the GC-C interacting protein IKEPP (intestinal and kidney-enriched PDZ protein), an adaptor protein closely related to PDZ1 found to be enriched at the apical membrane of human IEC has been described, but its role remains incompletely defined (Scott et al., 2002 ).
When we investigated the effect of MK571-mediated MRP4 inhibition on linaclotidestimulated extracellular transport of cGMP from rat colonic epithelium, we found selective inhibition of cGMP secretion from the apical membrane consistent with the subcellular localization of MRP4, but no effect on basolateral cGMP secretion suggesting the involvement of other cyclic nucleotide efflux pumps such as MRP5 in this process. While the involvement of This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 27, 2015 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org , 2014) . Notably, cGMP production following activation of GC-C occurs locally in close proximity to the apical membrane, but the mechanism(s) potentially involved in the translocation of cGMP to the basolateral cell membrane to drive extracellular transport, such as encapsulation into transport vesicles and/or passive diffusion, is currently not known.
Importantly, in recto-sigmoid mucosal biopsies of IBS-C patients, but not in IBS patients with mixed (IBS-M) bowel habits (constipation and diarrhea) MRP4 expression was found significantly down-regulated, compared to healthy subjects, while no changes in expression of the hormones guanylin and uroguanylin, GC-C and MRP5 were observed in either group.
However, immunohistochemistry revealed a spatially different pattern of MRP expression:
MRP4 located at the apical and MRP5 at the basolateral membrane of IEC, respectively (Harrington et al., 2014) . Together, these data show that distinct alterations are evident in the GC-C/cGMP pathway between different IBS subtypes that may contribute to the pathophysiology of IBS, which could further help explain some aspects of the symptom complex associated with IBS, such as differential stool frequency. Further consistent with this notion, Mrp4-deficient mice are more prone to CFTR-mediated secretory diarrhea than their wild-type littermates (Li et al., 2007) . On the molecular level, changes in MRP4 expression levels in IBS-C patients not only highlight the need to understand which proteins form the postulated GC-C interactome in IEC, but importantly, this knowledge could improve our understanding how specific changes in the composition of the GC-C interactome may contribute to disease.
In summary, these studies have demonstrated the presence of a previously unrecognized mechanism that functionally couples the secretory GC-C/cGMP pathway to spatially restricted compartmentalized modulation by the cyclic nucleotide efflux pump MRP4 at the apical membrane of the colonic epithelium. Translation of this concept into the clinic may have This article has not been copyedited and formatted. The final version may differ from this version.
important implications for patients suffering from gastrointestinal disorders such as IBS-C, CIC and secretory diarrhea, and MRP4 could evolve as a novel predictive biomarker in the clinic that may help stratify patients who would benefit most from GC-C agonist therapy.
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